Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102 : structural studies on specific CYP2D6substrate metabolism
Authors:
- 1 January 1997
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 27 (4) , 319-340
Abstract
1. A molecular model of CYP2D6 has been constructed from the bacterial form CYP102 via a homology alignment between the CYP2D subfamily and CYP102 protein sequences. 2. A number of typical CYP2D6 substrates are shown to fit the putative active site of the enzyme, as can the specific inhibitor quinidine. 3. Some of the allelic variants in CYP2D6, which give rise to genetic polymorphisms in 2D6-mediated metabolism, can be rationalized in terms of their position within the active site region. 4. The results of site-directed mutagenesis experiments are consistent with the CYP2D6 model generated from the CYP102 crystal structure. 5. The possibility of an alternative orientation within the active site may explain the CYP2D6-mediated metabolism of relatively large-sized substrates.Keywords
This publication has 18 references indexed in Scilit:
- Atypical Metabolism of Deprenyl and Its Enantiomer, (S)-(+)-N,.alpha.-Dimethyl-N-Propynylphenethylamine, by Cytochrome P450 2D6Chemical Research in Toxicology, 1994
- Role of Human Cytochromes P450 in the Metabolic Activation of Chemical Carcinogens and ToxinsDrug Metabolism Reviews, 1994
- Molecular evolution of P450 superfamily and P450‐containing monooxygenase systemsFEBS Letters, 1993
- Predicting the cytochrome P450 mediated metabolism of xenobioticsPharmacogenetics, 1993
- Correlation between site specificity and electrophilic frontier values in the metabolic hydroxylation of biphenyl, di-aromatic and CYP2D6 substrates: a molecular modelling studyXenobiotica, 1993
- Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeastBiochemical Pharmacology, 1992
- A tobacco smoke-derived nitrosamine, 4-(methytnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytocbrome P450s including the polymorphic human cytochrome P4502D6Carcinogenesis, 1991
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenololXenobiotica, 1986